Company Name, Ticker, Customers, else..

Vanda Pharmaceuticals Inc (NASDAQ: VNDA)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Vanda Pharmaceuticals Inc 's

Name: Vanda Pharmaceuticals Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VNDA Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Vanda Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by -3.92 %, despite the revenue increase by the most of its competitors of 18.45 %, recorded in the same quarter.

• List of VNDA Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Vanda Pharmaceuticals Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< VNDA Stock Performance Comparisons

Vanda Pharmaceuticals Inc 's Comment on Competition and Industry Peers

HETLIOZ® and HETLIOZ LQ® are protected by additional patents, some of which have been asserted against current generic competitors. The company is engaged in patent litigation to protect or enforce these patents, which may involve significant costs, time, and uncertain outcomes.

<< See the full list of VNDA competitors

Overall company Market Share Q2 2026

Overall company, revenue fell by -3.92 % and company lost market share, to approximately 2.22 %. << More on VNDA Market Share.

*Market share is calculated based on total revenue.

VNDA's Stock Performance relative to its Competitors

Publicly Traded Peers of Vanda Pharmaceuticals Inc

Climb Bio Inc
Share Performance

+1.78%

Over The Past 5 Days

Climb Bio Inc

Profile

The company develops clinical-stage therapeutics targeting immune-mediated diseases through the use of monoclonal antibodies.

More about Climb Bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,130.888 mill.	$ - mill.	$ -57.624 mill.

Opus Genetics Inc
Share Performance

+185.85%

This Year

Opus Genetics Inc

Profile

Opus Genetics develops gene therapies for inherited retinal diseases and other ophthalmic disorders.

More about Opus Genetics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 674.998 mill.	$ 9.856 mill.	$ -114.997 mill.

Kineta Inc
Share Performance

+68.05%

30 Days

Kineta Inc

Profile

Kineta, Inc. conducts its business primarily through Private Kineta's operations following a merger.

More about Kineta Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 4.336 mill.	$ 0.500 mill.	$ -8.463 mill.

Madrigal Pharmaceuticals Inc
Share Performance

-0.09%

30 Days

Madrigal Pharmaceuticals Inc

Profile

Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.

More about Madrigal Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 15,613.996 mill.	$ 1,283.940 mill.	$ -325.095 mill.

Mira Pharmaceuticals Inc
Share Performance

-19.86%

This Quarter

Mira Pharmaceuticals Inc

Profile

Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.

More about Mira Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 32.903 mill.	$ - mill.	$ -9.480 mill.

54 more competitors available

Sources: Vanda Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 12, 2026 6:57 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vanda Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.